CRAB Scientists Teach Brussels Statistics Workshop
Drs. John Crowley and Antje Hoering will teach the "Statistics in Clinical Oncology" workshop in Brussels, October 9-10, 2014. The event will feature two day-long modules that cover the following topics:
Module 1: Phase I and II Oncology Clinical Trials
Topics in early phases of oncology clinical trials (phase I-II) will be covered. Real world examples of recent SWOG and CRAB clinical trials will be given and trial designs will be demonstrated using CRAB's on-line calculators. The first half of the course will review basic concepts of oncology clinical trials including safety, efficacy and endpoint considerations. The most common phase I trial designs will be discussed. Single stage, two-stage phase II trial designs and randomized phase II trial designs, as well as pros and cons of these designs in various clinical settings, will be covered. The third edition of the Handbook of Statistics in Clinical Oncology edited by the instructors was published in the summer of 2012. The second half of the course will cover current topics in phase II oncology clinical trial designs based on this Handbook, including trial designs for cytostatic or targeted agents. Variations with targeted agents include dose exploration in seamless phase I/II trials; multiple strata phase II trials.
Module 2: Phase III Oncology Clinical Trials
Topics in phase III oncology clinical trials will be covered. Superiority and non-inferiority oncology phase III trials as well as DSMC issues will be reviewed. Real world examples of recent SWOG and CRAB clinical trials will be given and trial designs will be demonstrated using CRAB's on-line calculators. The third edition of the Handbook of Statistics in Clinical Oncology, edited by Drs. Crowley and Hoering, was published in the summer of 2012. The second half of the course will cover current topics in phase III oncology clinical trial designs based on this Handbook, including trial designs for cytostatic or targeted agents. Variations with targeted agents include phase II/III trials; and phase III designs for joint biomarker and drug development.
For more details about the event please visit the website:
CRAB Hosts Young Investigators Conference
The annual SWOG Young Investigators conference was hosted by CRAB September 29th through October 1st. The conference featured SWOG leadership members, CRAB data managers and six investigators who were introduced to the ways and means of SWOG protocol development, maintenance and administration.
For more details about the event please visit the SWOG website:
Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution
Seattle, WA. September 10, 2014 Seattle’s own Cancer Research And Biostatics (CRAB), and Translational Drug Development (TD2) in Scottsdale, would like to jointly announce CRAB’s assumption of responsibility for the PCRT, a world-renowned consortium comprised of a team of pancreatic cancer experts committed to improve treatment outcomes for patients with this deadly cancer.
Founded by leaders in pancreatic cancer clinical research, the PCRT is a consortium of more than 40 clinics and leading research institutions worldwide and serves as a premiere resource for the latest clinical trials. In addition, the PCRT provides a valuable collaborator for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer. This network provides the world's most coordinated effort dedicated to rapidly translating research discoveries into new treatments and care.
“Dr. John Crowley and CRAB have a distinguished record in clinical trials excellence. The PCRT has been working with the CRAB team for over ten years. It is gratifying to see CRAB take this growing group of devoted investigators to the next level”, said Daniel D. Von Hoff, M.D., FACP, Physician in Chief, Distinguished Professor, Translational Genomics Research Institute (TGen), Chief Scientific Officer, Scottsdale Healthcare, and one of the Founders and current Board member of PCRT.
You may access the full press release at this link: http://www.prweb.com/releases/2014/9/prweb12163611.htm